BACKGROUND: Fabry disease (FD) is a rare and treatable X-linked lysosomal storage disorder. Cardiac involvement determines outcomes; therefore, detecting early changes is important. Native T1 by cardiovascular magnetic resonance is low, reflecting sphingolipid storage. Early phenotype development is familiar in hypertrophic cardiomyopathy but unexplored in FD. We explored the prehypertrophic cardiac phenotype of FD and the role of storage.

METHODS AND RESULTS: A prospective, international multicenter observational study of 100 left ventricular hypertrophy–negative FD patients (mean age: 39±15 years; 19% male) and 35 age- and sex-matched healthy volunteers (mean age: 40±14 years; 25% male) who underwent cardiovascular magnetic resonance, including native T1 and late gadolinium enhancement, and 12-lead ECG. In FD, 41% had a low native T1 using a single septal region of interest, but this increased to 59% using a second slice because early native T1 lowering was patchy. ECG abnormalities were present in 41% and twice as common with low native T1 (53% versus 24%; P=0.005). When native T1 was low, left ventricular maximum wall thickness, indexed mass, and ejection fraction were higher (maximum wall thickness 9±1.5 versus 8±1.4 mm, P<0.005; indexed left ventricular mass 63±10 versus 58±9 g/m², P<0.05; and left ventricular ejection fraction 73±8% versus 69±7%, P<0.01). Late gadolinium enhancement was more likely when native T1 was low (27% versus 6%; P=0.01). FD had higher maximal apical fractal dimensions compared with healthy volunteers (1.27±0.06 versus 1.24±0.04; P<0.005) and longer anterior mitral valve leaflets (23±2 mm versus 21±3 mm; P<0.005).

CONCLUSIONS: There is a detectable prehypertrophic phenotype in FD consisting of storage (low native T1), structural, functional, and ECG changes.
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the gene (GLA) encoding for α-galactosidase A. Slowly progressive sphingolipid accumulation affects multiple organs, including the heart. 1 Cardiac and renal involvement drives outcome in FD with cardiovascular death being the leading cause of death in FD. 2–4 Cardiac manifestations include left ventricular hypertrophy (LVH), arrhythmias, chronic inflammation, 5 myocardial fibrosis, and functional impairment. 6 Among the suggested risk factors for ventricular arrhythmias and sudden cardiac death were LVH and myocardial fibrosis. 3 Although oral chaperone has now become available for amenable mutations, 7 the mainstay of therapy has been enzyme replacement therapy (ERT), which is expensive, less effective after the onset of fibrosis, and does not entirely reverse established LVH suggesting that best outcomes may occur with early initiation of ERT. 8 Early phenotypic markers of FD cardiac involvement are, therefore, needed.

The link of sphingolipids to cardiac disease is not well understood. Although storage is thought to be a primary factor, toxic circulating metabolites may play a role. 9 An advance was the identification by cardiovascular magnetic resonance (CMR) of late gadolinium enhancement (LGE), which characteristically occurs initially in the basal inferolateral wall. 10 Histological correlation in advanced disease confirmed it represented focal fibrosis. 11 However, LGE is generally considered a late feature in FD, 12,13 although it may occur before LVH in females. 14 CMR allows quantitative characterization of the myocardium using 3 fundamental magnetic tissue relaxation constants, T1, T2, and T2* , and displays them as parametric color maps. Native T1 is low, representing sphingolipid accumulation, 15,16 in 85% of FD with LVH and 40% to 50% of LVH-negative patients, suggesting storage occurs early. 15,17 ECG changes are known to sometimes precede echocardiographic LVH, 18,19 and elevated levels of serum cardiac biomarkers (troponin and NT-proBNP [N-terminal pro-B-type natriuretic peptide]) have also been described. 5,20,21 In sarcomeric hypertrophic cardiomyopathy (HCM), a preclinical phenotype is present with, among other features, multiple myocardial crypts, anterior mitral valve leaflet (AMVL) elongation, abnormal trabeculae, and a higher ejection fraction. 22 We sought a prehypertrophic cardiac phenotype in FD—looking for whether storage, ECG changes, subtle structural and functional abnormalities, and blood biomarkers cosegregate.

CLINICAL PERSPECTIVE
Cardiovascular death is the leading cause of the death in Fabry disease in both males and females. As it is a treatable disease, detection of early cardiac involvement is important. Treatment seems less effective once fibrosis and overt left ventricular hypertrophy occur; however, treatment is onerous and expensive thus phenotypic justification is required to commence patients on treatment. Low native myocardial T1 reflects sphingolipid accumulation and has promising potential in early detection in the prehypertrophic Fabry disease population. We have concluded that low native T1 is patchy in the LVH-negative population and is more common than previously reported (prevalence increased to 59%) by measuring regions of interests in at least 2 short-axis slices and inspection of color maps with appropriate lookup tables. Multiple abnormalities cosegregate with low native T1. ECG abnormalities were present in 41% and were twice as common when native T1 was low. LV maximum wall thickness, indexed mass, and ejection fraction were higher with low native T1. LGE was 5 times more likely when native T1 was low. Thirty-one percent of patients were found to have both low native T1 and ECG abnormalities; therefore, we hypothesized that this subgroup is most likely to progress, and early treatment in this subgroup may have the most clinical impact.

 Methods
The imaging data and study materials are all anonymized and centralized on a REDCap server and are available to other researchers for purposes of reproducing the results or replicating the procedure if requested.

Study Population
This is a prospective, multicenter international observational study in 100 LVH-negative FD patients as a part of the Fabry400 study (NCT03199001). Participants were recruited from 4 Fabry clinics (United Kingdom: Royal Free Hospital London, National Hospital for Neurology and Neurosurgery London, and Queen Elizabeth Hospital Birmingham; Australia: Westmead Hospital Sydney). This study was approved by the National Research Ethics Service ethical committee and conformed to the principles of the Helsinki Declaration. Written informed consent was obtained from all participants. Inclusion criteria were as follows:

1. FD (n=100): all gene-positive LVH-negative males and females with left ventricular (LV) maximum wall thickness (MWT) <13 mm and LV mass (LVM) within the normal reference ranges by CMR according to body surface area, age, and sex. 23
2. Healthy volunteers (HV, n=35): all prospectively recruited with no history of cardiovascular disease (normal health questionnaire and on no cardioactive medication unless for primary prevention).

Exclusion criteria were as follows: We excluded patients with standard contraindications to CMR and pregnancy. All

Circ Cardiovasc Imaging. 2018;11:e007168. DOI: 10.1161/CIRCIMAGING.117.007168 June 2018 2
participants underwent CMR and ECG. All participants had estimated glomerular filtration rate blood samples collected. The blood for serological biomarkers was systematically obtained by the time of the intravenous access and analyzed for high-sensitivity troponin T (United Kingdom) and high-sensitivity troponin I (Australia) (Roche Diagnostic; normal range 0–14 ng/L for troponin T and 0–15 ng/L for troponin I), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) analysis (Roche Diagnostics; normal range according to age and sex).20 As a result, NT-proBNP and troponin results were available in majority of patients (76% and 73%). The missing blood values were because of patient refusal of gadolinium contrast agent (n=12), absence of research clinical fellow support at the scanner (n=10), and hemolyzed (n=2 for NT-proBNP; n=5 for troponin).

CMR Imaging
All participants underwent CMR at 1.5 Tesla (Avanto (United Kingdom) and Aera (Australia); Siemens Healthcare, Erlangen, Germany) using a standard clinical protocol with LGE imaging using phase sensitive inversion recovery. T1 mapping was performed precontrast bolus administration (0.1 mmol/kg body weight, gadoterate meglumine; Dotarem, Guerbet S.A., France) on basal and mid left ventricular short-axis slices using a shortened modified Look-Locker inversion recovery (ShMOLLI) sequence. The resulting pixel-by-pixel T1 color maps were displayed using a customized 12-bit lookup table, where normal myocardium was green, increasing native T1 was red, and decreasing native T1 was blue. Post-T1 mapping was performed 15 minutes after contrast administration for extracellular volume (ECV) fraction quantification.

CMR Analysis
All images were centralized and analyzed using CVI42 software (Circle Cardiovascular Imaging, Inc, Calgary, Canada). The analysis plan was for a region of interest (ROI) avoiding the blood–myocardial boundary (20% offset) manually drawn in the basal septum,24 but visual inspection of the color maps showed that native T1 lowering (blue areas) could be patchy so 6 segments in basal and mid short-axis slices were used in further analyses (Figures 1 and 2). Normal native T1 reference ranges (mean±2 SD) were defined using age- and sex-matched HV from each individual center, taking into account the native T1 regional variations in HV from each center.

The normal native septal T1 ranges (mean, 1 SD, and lower limit of normal) for each center were London center: mean 968±32 ms and lower limit 904 ms in total population; mean 956±27 ms and lower limit 902 ms in male subgroup; and mean 978±34 ms and lower limit 910 ms in female subgroup. Birmingham center: mean 959±32 ms and lower limit 895 ms in total population; mean 947±28 ms and lower limit 890 ms in male subgroup; and mean 958±30 ms and lower limit 898 ms in female subgroup. Sydney center: mean 958±31 ms and lower limit 896 ms in total population; mean 947±24 ms and lower limit 893 ms in male subgroup; and mean 965±31 ms and lower limit 903 ms in female subgroup.

The T1 Mapping and ECV Standardization Program phantom was scanned as part of the The T1 Mapping and

![Figure 1. A patient with obvious but missed low native T1. Top: The usual approach is to draw one region of interest (ROI) in a single short-axis (SA) slice. This generated a normal native T1 (932 ms). Note, however, there is blue myocardium in the second, unmeasured slice. By drawing other ROIs on both slices (bottom), the low native T1 is captured.](image-url)
ECV Standardization Program multicenter study according to the user manual instructions distributed to centers and as previously described. The London site coefficient of variation for reads varied from 0.512 to 1.460 at mean temperature of 21. Sydney site coefficient of variation for reads varied from 0.033 to 1.169 at mean temperature 21. Intersite reads across the 9 tubes were consistent (all P>0.05): the mean differences in measured T1 across all tubes were 10.30±5.71 (SD) ms between sites. Considering only the tubes emulating normal native myocardial T1 and low native myocardial T1 (that are relevant to FD in this article), the mean differences in measured T1 between sites was 9.52±3.64 (SD) ms.

We used the differential methods for quantification of LV volumes (excluding left ventricular papillary mass [LVPM]) and LVM (including LVPM) by manual contouring of LVPM (Figure I in the Data Supplement). Automated (threshold-dependent) methods have not been used. The LVPM were reported as absolute mass.

AMVL measurements and myocardial crypt counts (considering only ≥2) followed published methodologies. For trabeculae, LV fractal analysis was performed on the LV short-axis cine stack using the cvi42 fractal plugin as previously described deriving the following fractal dimensions: mean whole heart (fractal dimensionmean) and maximal apical (fractal dimensionmaxapical).

RESULTS

There were 135 participants: 100 FD and 35 HV. Recruitment was from London, Birmingham, and Sydney.

ECG Analysis

Twelve-lead ECG was prospectively performed on all participants. The ECGs were independently analyzed by 2 experienced observers (S.N. and S.B.). Recorded ECG variables included heart rate, rhythm, PR interval duration (normal 120–200 ms), QRS complex duration (normal <120 ms), and QTc interval duration (normal >440 ms for males and >460 ms for females). The presence of complete left or right bundle branch block, T-wave inversion in at least 2 contiguous leads, multifocal ventricular ectopics, and Sokolow–Lyon voltage criteria for LVH (SV1+RV5 or RV6 >35 mm) were also recorded.

Statistical Analysis

Statistical analyses were performed using SPSS 24 (IBM, Armonk, NY). Continuous variables were expressed as mean±SD or median (interquartile range [IQR]) according to normality (Shapiro–Wilk test); categorical variables were expressed as percentages. Group testing was independent-sample t test, Mann–Whitney U, χ² test, or Fisher exact test as appropriate (normality, categorical, or continuous). Comparisons between 3 groups were performed by 1-way ANOVA with post hoc Bonferroni correction. The Bland–Altman test and intraclass correlation coefficient were used to assess intra- and interobserver variability of native T1. The coefficient of variation between repeated phantom scans was calculated as a measure of reproducibility. A P value of <0.05 was considered significant.

Table 1. Demographic Characteristics of the Healthy Volunteers and Fabry Disease Cohort

|                          | Healthy Volunteer (n=35) | Fabry Disease (n=100) | P Value |
|--------------------------|-------------------------|-----------------------|---------|
| Age, y                   | 40±14                   | 39±15                 | 0.724   |
| Male, n (%)              | 9 (25)                  | 19 (19)               | 0.235   |
| BSA, m²                  | 1.73±0.20               | 1.79±0.21             | 0.104   |
| Heart rate, bpm          | 66±10                   | 62±12                 | 0.084   |
| Systolic BP, mmHg        | 121±13                  | 116±14                | 0.038*  |
| Diastolic BP, mmHg       | 76±10                   | 72±9                  | 0.012*  |
| Hypertension, n (%)      | 0                       | 8 (8)                 | 0.112   |
| CAD, n (%)               | 0                       | 2 (2)                 | 1       |
| eGFR, ml/min per 1.73 m2 | 86±6                    | 86±8                  | 0.782   |
| ERT, n (%)               | N/A                     | 38 (38)               | ...     |
| Cardiac variant, n (%)   | N/A                     | 34 (34)               | ...     |
| LVEF (%)                 | 67±4                    | 71±7                  | 0.002*  |
| LVWT, mm                 | 9±1.3                   | 9±1.5                 | 0.368   |
| LVMi, g/m²               | 63±14                   | 61±10                 | 0.243   |
| LVESVi, ml/m²            | 73±12                   | 72±11                 | 0.728   |
| LVPM, g                  | 24±6                    | 21±7                  | 0.012*  |
| AMVL, mm                 | 6±2                     | 8±4                   | 0.027*  |
| Crypts, n (%)            | 1 (3)                   | 9 (9)                 | 0.288   |
| Fractal dimensionmaxapical | 1.2377±0.04            | 1.2674±0.06           | 0.005*  |

Heart rate and blood pressure were taken at the time of study visit. AMVL indicates anterior mitral valve leaflet; BP, blood pressure; BSA, body surface area; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; LVEDVi, left ventricular end-diastolic volume indexed to BSA; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end-systolic volume indexed to BSA; LVMI, left ventricular mass indexed to BSA; LVPM, left ventricular papillary muscle; MWT, maximum wall thickness; and N/A, not applicable.

*P<0.05 considered as statistically significant.
with native T1 (low native T1 subgroup median 7 years [IQR: 5.5–9.5 years] versus normal native T1 subgroup 9 years [IQR: 7–11 years]; P=0.12) or ECG abnormalities (abnormal ECG subgroup median 8 years [IQR: 5.5–10 years] versus normal ECG subgroup 9 years [IQR: 7–10 years]; P=0.17).

**Myocardial Abnormalities**

**Function and Mass**

All FD patients had normal LV MWT, LV cavity size, and mass and mass-to-volume ratios <1. MWT in the FD and HV cohorts were similar (9±1.5 versus 9±1.3 mm; P=0.4). Indexed LVM (LVMi) and LV end-diastolic volume were similar to HV (LVMi 61±10 versus 63±14 g/m²; P=0.20 and LV end-diastolic volume 72±11 versus 73±12 mL/m²; P=0.7), but LV end-systolic volume was smaller in FD (21±7 versus 24±6 mL/m²; P=0.012). All patients had normal or supranormal LV systolic function, and overall, the LVEF in FD was higher than HV (71±7% versus 67±4%; P=0.002).

**Native T1 Reproducibility**

Native T1 intra- and interobserver variability (n=30) were good—the low native T1 areas are obvious when displayed with an appropriate lookup table (Figure 2). Intraclass correlation coefficients (intraobserver then interobserver) in the septum were 0.995 and 0.986, respectively, and ROIs elsewhere: 0.983 and 0.986. Bland–Altman graphs did not show systemic bias (Figure II in the Data Supplement).

**Myocardial LGE**

Sixteen FD had LGE (13 basal inferolateral wall and 3 right ventricular insertion points). No HV had LGE.

**Myocardial ECV**

The ECV measured from a septal ROI was normal in all participants (FD 0.27±0.03 versus HV 0.28±0.03; P=0.46).

**ECG**

In FD, 41% (41/100) had abnormal ECGs. There were 4 patients with other potential causes of ECG abnormalities (n=1 coronary artery disease; n=3 hypertension). All HV ECGs were normal.

**Blood Biomarkers**

Of the FD patients, 73% had high-sensitivity troponin and 76% had NT-proBNP measured. Ten percent (7/73) had raised high-sensitivity troponin levels and 16% (12/76) had raised NT-proBNP.

**Papillary Muscles**

Papillary muscle mass was higher in FD (8±4 versus 6±2 g; P<0.05).

**Myocardial Architecture**

In FD compared with HV, the anterior mitral valve leaflet was longer (23±2 versus 21±3 mm; P=0.002). Nine percent (9/100) of FD and 3% (1/35) of HV had crypts (P>0.05). Compared with HV, FD had abnormal trabeculae at the apex resulting in higher fractal dimensionmaxapical (1.27±0.06 versus 1.24±0.04; P<0.005). Fractal dimensionmean were similar to HV (1.22±0.03 versus 1.23±0.03; P=0.10).

**Cosegregation of Early Changes**

**Native T1 and ECG**

Of the patients with abnormal ECGs, 76% (31/41) had low native T1. ECG abnormalities were more than twice as common when the T1 was low (53%, 31/59 versus 24%, 10/41; P=0.005). The ECG abnormalities observed were (low native T1 versus normal native T1) Sokolow (19% versus 7%), T-wave inversion (13% versus 7%), short PR (12% versus 5%), and long PR intervals (9% versus 2%; Figure 3). QRS interval, QTc interval, and Sokolow–Lyon voltages were higher in the low native T1 subgroup than that in the normal native T1 FD subgroup and HV (Table 2).

**Native T1 and LV Function/Mass**

MWT, LVMi, and EF were higher in low native T1 than that in normal native T1 FD (MWT 9±1.5 versus 8±1.4 mm, P<0.005; LVMi 63±10 versus 58±9 g/m², P<0.05; EF 73±8% versus 69±7%, P<0.01). LV end-diastolic volume index, LV end-systolic volume index, and mass-to-volume ratio were the same. Normal native T1 patients were the same as HV for all parameters.

**Native T1 and LGE**

LGE was ≈5 times as common in the low native T1 FD subgroup compared with the normal native T1 FD subgroup (27%, 14/52 versus 6%, 2/34; P=0.01). Eighty-seven percent (13/15) with LGE had low native T1 (Figure 4). One patient with normal native T1 and LGE had both a history of hypertension and coronary artery disease; however, the LGE pattern in this patient was typical of Fabry (midwall basal inferolateral).

**Native T1 and ECV**

ECV was the same in low native T1, normal native T1, and HV (0.27±0.03 versus 0.28±0.03 versus 0.28±0.03; all P=0.56).
**Native T1 and Blood Biomarkers**

Although most patients with elevated biomarkers had low T1 (71%, 5/7 for high-sensitivity troponin; 58%, 7/12 for NT-proBNP), differences were not significant.

**Native T1 and Papillary Muscles**

With low native T1, papillary muscle mass was higher ($P=0.003$). Normal native T1 patients had similar papillary muscle mass as HV (low native T1 FD 8±4 g versus normal native T1 FD 6±3 g versus HV 6±2 g). Papillary muscle mass increase was not out of proportion to compacted myocardial hypertrophy, however.

**Native T1 and AMVL/Fractal Dimension**

AMVL elongation and the increased apical fractal dimension were storage independent and not confined to the low native T1 group—AMVL elongation and increased apical fractal dimension were the only variables different between normal native T1 FD and HV (AMVL normal native T1 versus HV: 24±3 versus 21±3 mm; $P=0.004$).

![Figure 2. Spectrum of native T1 in left ventricular hypertrophy–negative Fabry disease with corresponding late gadolinium enhancement (LGE) images.](image)

Patient 1: Normal native T1 in both basal and mid short axis (SA). Patient 2: Patchy low native T1 in the lateral walls. Patient 3: Patchy low native T1 mainly in both SA slices. Patient 4: Patchy low native T1 in the mid SA septum but normal native T1 in basal SA. Patient 5: low native T1 all across both SA.
and fractal dimension, normal native T1 versus HV: 1.27±0.05 versus 1.24±0.04; P=0.01).

**Other Comparisons**

**LGE and Blood Biomarkers**

Half of the patients with LGE had raised troponin. No other patients had raised troponin (45%, 5/11 versus 0%, 0/57; P<0.001). There was no significant difference in the prevalence of raised NT-proBNP in the LGE-positive and LGE-negative subgroups (17%, 2/10 versus 14%, 8/59; P=0.29).

**ERT and ERT-Naive**

There was no significant difference between proportion of low T1, abnormal ECG, LGE, raised troponin, and NT-proBNP between the ERT and ERT-naive subgroups. There was also no significant difference between the MWT, LVMI, LVEF, and ECG between these subgroups.

**Males and Females**

There are higher proportions of males with low T1 and abnormal ECG compared with females (low T1 male 79%, 15/19 versus female 54%, 44/81; P<0.05 and abnormal ECG male 63%, 12/19 versus female 36%, 29/81; P<0.05). Males have higher MWT (10±1.3 versus 9±1.5 mm; P<0.001) and LVMI (71±10 versus 59±9 g/m²; P<0.001), and females have higher LVEF (73±7% versus 66±8%; P=0.001). Ninety-four percent (15/16) with LGE were female; the 1 male had LGE at right ventricular insertion point.

**DISCUSSION**

These data show that there is a prehypertrophic FD phenotype. In LVH-negative FD, storage (low native T1) is patchy and more common (prevalence 59%) than previously reported.15,17 Multiple other abnormalities are found. Most of these cluster with low native T1–ECG changes, higher EF, higher mass (within the normal range), larger papillary muscles, and LGE (Table 3). There are, however, 2 exceptions: first, troponin is associated with LGE rather than directly with storage (as in overt disease5) and second, anterior mitral valve leaflet and abnormal apical trabeculae (known markers of preclinical sarcomeric HCM22) are also present in prehypertrophic FD and seem to be storage independent. Diffuse fibrosis (ECV) and NT-proBNP were not useful. Overall, these data suggest first that storage is a key part of FD phenotype development and second that there is a storage-independent FD phenotype with some of its features, recapitulating those seen in preclinical sarcomeric HCM,22

Figure 3. Comparison of ECG abnormalities between low native T1 and normal native T1 Fabry disease subgroups.

AF indicates atrial fibrillation; BBB, bundle branch block; and VE, ventricular ectopics.

Table 2. ECG Parameters of Healthy Volunteers, Low Native T1 Fabry Disease, and Normal Native T1 Fabry Disease

|                  | Healthy Volunteer | Low Native T1 Fabry Disease | Normal Native T1 Fabry Disease | P Value |
|------------------|-------------------|-----------------------------|-------------------------------|---------|
| PR interval, ms  | 158±17            | 147±26                      | 147±26                        | 0.08    |
| QRS duration, ms| 85±9              | 93±14                       | 88±10                         | 0.005   |
| QTc interval, ms | 394±26            | 411±27                      | 407±21                        | <0.01   |
| Sokolow, mm      | 21±7              | 27±8                        | 23±10                         | <0.005  |

Figure 4. Normal versus abnormal ECG and late gadolinium enhancement (LGE)–positive vs LGE-negative in the low native T1 and normal native T1 Fabry disease (FD) subgroups showing ECG abnormalities are found in 76% vs 24% (P=0.005) and LGE in 87% versus 13% (P=0.01).
HCM may be described: in both, ECG abnormalities occur early along with hyperdynamic function and mass increases within the normal range. AMVL elongation and increased endocardial complexity at the apex suggesting abnormal trabeculae are features common to both (Figure 5). The spectrum of ECG abnormalities is similar, although a short PR is occasionally observed here in FD. Differences include the native T1 lowering (unique to FD), the absence of crypts (crypts occur in preclinical HCM, particularly MYBPC3, and are detectable in all mice in utero as part of normal development), early papillary muscle mass increase, and LGE as a pre-LVH FD feature in females, linking to troponin elevation.

To date, T1 mapping has added diagnostic value in overt LVH where elevation (mainly amyloid) and lowering (only FD or dual pathology: iron overload and a separate LVH cause) are highly sensitive and specific.17 In the absence of histological confirmation, a low native T1 caused by cardiac iron overload is usually obvious from history and examination of the patient and extracardiac findings in CMR such as dark appearance of the liver and extra medullary hematopoiesis.

These data add support to the use of a low native T1 to identify prehypertrophic or early cardiac involvement in FD and may be a candidate starting criteria for early treatment in either practice or in clinical trials. We highlight that more than one ROI and inspection of color maps with appropriate lookup tables are needed to maximize sensitivity for early storage. ECG changes have been known to precede echocardiographic features18,19 but may be nonspecific.33 A low native T1 if at the detection limit could also generate false positives.

Table 3. Comparison Between Low Native T1 and Normal Native T1 Fabry Disease With ECG, LGE, Troponin, NT-proBNP, MWT, LVMi, and LVEF

|                      | Low Native T1 | Normal Native T1 | P Value |
|----------------------|--------------|-----------------|---------|
| ECG (n=100)          |              |                 | 0.005   |
| Abnormal             | 31           | 10              |         |
| Normal               | 28           | 31              |         |
| LGE (n=88)           |              |                 | 0.01    |
| Positive             | 14           | 2               |         |
| Negative             | 38           | 34              |         |
| Troponin (n=73)      |              |                 | 0.45    |
| Raised               | 5            | 2               |         |
| Normal               | 35           | 31              |         |
| NT-proBNP (n=76)     |              |                 | 0.89    |
| Raised               | 7            | 5               |         |
| Normal               | 36           | 28              |         |
| Structure and function (n=100) |          |                 |         |
| MWT, mm              | 9±1.5        | 8±1.4           | <0.005  |
| LVMi, g/m²           | 63±10        | 58±9            | <0.05   |
| LVEF, %              | 73±8         | 69±7            | <0.01   |

BSA indicates body surface area; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass indexed to BSA; MWT, maximum wall thickness; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.

Figure 5. Example of a Fabry disease (FD) patient with low native T1 and no late gadolinium enhancement (LGE) with abnormal ECG (T-wave inversion in leads III, aVF, V4 through V6). Anterior mitral valve leaflet (AMVL) elongation (24 mm) and hypertrabeculation (fractal dimensions 1.32) were also present; these latter 2 features, however, are native T1-independent.
How could ECG and native T1 be used in combination clinically? Cardiac involvement by ECG abnormalities only was 41%; 59% by low native T1 only. However, cardiac involvement by an either ECG abnormalities or low native T1 approach is 69% by either or 31% by both (Table 3). In LVH-negative FD, it is the low native T1 and abnormal ECG cohort that we hypothesized is most likely to progress and may benefit most from early intervention. The other features identified here (subtle LVM elevation or increased EF) are more between-group differences.

We do not know the mechanism linking low native T1 with ECG abnormalities, but others have shown globotriaosylceramide (GB3) around the atroventricular node might cause PR-interval shortening, therefore accelerating atroventricular conduction rather than accessory pathways. This is likely because of progressive deposition of GB3 in cardiac conduction tissue causing cellular dysfunction. Over time, there is evidence of PR prolongation and increasing QRS duration. This has been attributed to fibrosis, amyloid, vasodilatation, and edema) in native T1 are possible given the lack of a direct histological comparison in this article. To date, there is a measurable early phenotype in pre-hypertrophic FD, including low native T1, ECG abnormalities, LGE, LVM, wall thickness, and ejection fraction elevation. Increased trabeculation and elongation of the anterior leaflet of the mitral valve are also seen.

CONCLUSIONS

Storage in LVH-negative FD is more common than previously described because early native T1 lowering may be patchy. There is a measurable early phenotype in pre-hypertrophic FD, including low native T1, ECG abnormalities, LGE, LVM, wall thickness, and ejection fraction elevation. Increased trabeculation and elongation of the anterior leaflet of the mitral valve are also seen.

ARTICLE INFORMATION

Received September 26, 2017; accepted March 29, 2018. The Data Supplement is available at http://circimaging.ahajournals.org/lookup/suppl/doi:10.1161/CIRCIMAGING.117.007168/-/DC1.

Correspondence

James C. Moon, MD, Barts Heart Centre, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, United Kingdom. E-mail:j.moon@ucl.ac.uk

Affiliations

Cardiology Department, Barts Heart Centre, London, United Kingdom (S.N., A.A.-G., K.M.-M., S.R., G.C., J.C.M.). Institute of Cardiovascular Science, University College London, United Kingdom (S.N., A.A.-G., K.M.-M., G.C., J.C.M.). Sydney Medical School, University of Sydney, Australia (R.K.). Cardiology Department (S.B., N.C.E., R.P.S.) and Inherited Metabolic Disorders Unit (T.H.), University Hospitals Birmingham, United Kingdom. Department of Genetic Medicine, Westmead Hospital, Australia (M.T.). Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, United Kingdom (E.M., R.L.). Lyssosomal Storage Disorder Unit, Royal Free Hospital, London, United Kingdom (U.R., D.H.).

Acknowledgments

This research is supported by researchers at the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

Sources of Funding

This study is part of the Fabry400 study, which is funded by an investigator-led research grant from Genzyme.

Disclosures

None.

REFERENCES

1. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–1435. doi: 10.1016/S0140-6736(08)61589-5.
2. Wang S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11:790–796. doi: 10.1097/GIM.0b013e3181b8195b.
3. Baig S, Edwards N, Kotecha D, Liu B, Nordin S, Kozor R, Moon JC, Geberhiwot T, Steeds RP. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review and identification of risk factors in clinical practice [published online ahead of print October 17, 2017]. Europace. doi: 10.1093/europace/eux261. https://academic.oup.com/europace/advance-article-abstract/doi/10.1093/europace/eux261/4555480?redirectedFrom=fulltext. Accessed April 24, 2018.
4. Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nichols K, Stotmann J, Tallaj J, Tran TC, West ML, Beitner-Johnson D, Abi-Serie A. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol. 2011;57:1093–1099. doi: 10.1016/j.jacc.2010.11.018.
5. Nordin S, Kozor R, Bullock H, Castelletti S, Rosmini S, Abdel-Gadir A, Baig S, Mehta A, Hughes D, Moon JC. Cardiac Fabry disease with late gado-
anti-bradycardia pacing in patients with Anderson-Fabry disease. Euro-
pace. 2011;13:1781–1788. doi: 10.1093/ephv/eur267.
37. Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabry’s disease with a short PR interval. Am J Cardiol. 1994;74:203–204.
38. Ikari Y, Kuwako K, Yamaguchi T. Fabry’s disease with complete atrioven-
tricular block: histological evidence of involvement of the conduction sys-
tem. Br Heart J. 1992;68:323–325.
39. Sheppard MN, Cane P, Florio R, Kavantzas N, Close L, Shah J, Lee P, Elliott P. A detailed pathologic examination of heart tissue from three older pa-
tients with Anderson-Fabry disease on enzyme replacement therapy. Car-
diovasc Pathol. 2010;19:293–301. doi: 10.1016/j.carpath.2009.05.003.
40. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007;93:528–535. doi: 10.1136/hrt.2005.063818.
41. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta A8. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-
Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94:153–158. doi: 10.1136/hrt.2006.104026.